Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase Ib/II Clinical Study of PARP Inhibitor CVL218 in Combination With Therapy in Patients With Advanced Solid Tumors

Next Previous
Trial Profile

Phase Ib/II Clinical Study of PARP Inhibitor CVL218 in Combination With Therapy in Patients With Advanced Solid Tumors

Status: Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fruquintinib (Primary) ; Mefurapiride hydrochloride (Primary) ; Paclitaxel (Primary) ; Sintilimab (Primary) ; Toripalimab (Primary)
  • Indications Advanced breast cancer; Biliary cancer; Bladder cancer; Colorectal cancer; Gastric cancer; Glioma; Intestinal cancer; Lung cancer; Male breast cancer; Malignant melanoma; Pancreatic cancer; Prostate cancer; Triple negative breast cancer
  • Focus Adverse reactions
  • Sponsors Shanghai Institute of Materia Medica

Most Recent Events

  • 30 Apr 2025 Results assessing efficacy and safety of CVL218 combined with PD-1antibody and paclitaxel nanoparticle albumin-bound in patients with TNBC who have failed previous first-line treatment, presented at the 116th Annual Meeting of the American Association for Cancer Research.
  • 09 Oct 2023 Status changed from planning to not yet recruiting.
  • 25 Feb 2022 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top